company background image
ACGN

Aceragen NasdaqCM:ACGN Stock Report

Last Price

US$4.71

Market Cap

US$39.9m

7D

-4.7%

1Y

-52.9%

Updated

30 Jan, 2023

Data

Company Financials

ACGN Stock Overview

Aceragen, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of drugs for rare pulmonary and rheumatic diseases in the United States.

ACGN fundamental analysis
Snowflake Score
Valuation1/6
Future Growth0/6
Past Performance0/6
Financial Health6/6
Dividends0/6

My Notes

New

Notes are coming soon

Aceragen, Inc. Competitors

Price History & Performance

Summary of all time highs, changes and price drops for Aceragen
Historical stock prices
Current Share PriceUS$4.71
52 Week HighUS$16.00
52 Week LowUS$3.66
Beta1.3
1 Month Change-20.84%
3 Month Change-42.28%
1 Year Change-52.89%
3 Year Change-82.68%
5 Year Change-98.11%
Change since IPO-99.99%

Recent News & Updates

Idera Pharmaceuticals completes acquisition of Aceragen

Sep 28

We're Keeping An Eye On Idera Pharmaceuticals' (NASDAQ:IDRA) Cash Burn Rate

Aug 24
We're Keeping An Eye On Idera Pharmaceuticals' (NASDAQ:IDRA) Cash Burn Rate

Recent updates

We're Keeping An Eye On Idera Pharmaceuticals' (NASDAQ:IDRA) Cash Burn Rate

Aug 24
We're Keeping An Eye On Idera Pharmaceuticals' (NASDAQ:IDRA) Cash Burn Rate

We Think Idera Pharmaceuticals (NASDAQ:IDRA) Needs To Drive Business Growth Carefully

May 11
We Think Idera Pharmaceuticals (NASDAQ:IDRA) Needs To Drive Business Growth Carefully

Is Idera Pharmaceuticals (NASDAQ:IDRA) In A Good Position To Deliver On Growth Plans?

Mar 07
Is Idera Pharmaceuticals (NASDAQ:IDRA) In A Good Position To Deliver On Growth Plans?

When Will Idera Pharmaceuticals, Inc. (NASDAQ:IDRA) Become Profitable?

Jan 31
When Will Idera Pharmaceuticals, Inc. (NASDAQ:IDRA) Become Profitable?

Could The Idera Pharmaceuticals, Inc. (NASDAQ:IDRA) Ownership Structure Tell Us Something Useful?

Dec 27
Could The Idera Pharmaceuticals, Inc. (NASDAQ:IDRA) Ownership Structure Tell Us Something Useful?

Don't Ignore The Fact That This Insider Just Sold Some Shares In Idera Pharmaceuticals, Inc. (NASDAQ:IDRA)

Dec 27
Don't Ignore The Fact That This Insider Just Sold Some Shares In Idera Pharmaceuticals, Inc. (NASDAQ:IDRA)

We're Keeping An Eye On Idera Pharmaceuticals' (NASDAQ:IDRA) Cash Burn Rate

Nov 25
We're Keeping An Eye On Idera Pharmaceuticals' (NASDAQ:IDRA) Cash Burn Rate

Shareholder Returns

ACGNUS BiotechsUS Market
7D-4.7%0.8%2.8%
1Y-52.9%7.1%-9.2%

Return vs Industry: ACGN underperformed the US Biotechs industry which returned 7.1% over the past year.

Return vs Market: ACGN underperformed the US Market which returned -9.2% over the past year.

Price Volatility

Is ACGN's price volatile compared to industry and market?
ACGN volatility
ACGN Average Weekly Movement24.8%
Biotechs Industry Average Movement12.2%
Market Average Movement6.9%
10% most volatile stocks in US Market17.3%
10% least volatile stocks in US Market2.8%

Stable Share Price: ACGN is more volatile than 90% of US stocks over the past 3 months, typically moving +/- 25% a week.

Volatility Over Time: ACGN's weekly volatility has increased from 17% to 25% over the past year.

About the Company

FoundedEmployeesCEOWebsite
198913John Taylorhttps://www.aceragen.com

Aceragen, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of drugs for rare pulmonary and rheumatic diseases in the United States. Its clinical development pipeline includes ACG-701 for acute pulmonary exacerbations in cystic fibrosis, as well as for melioidosis; and ACG-801 for farber disease. The company was formerly known as Idera Pharmaceuticals, Inc. and changed its name to Aceragen, Inc. in January 2023.

Aceragen, Inc. Fundamentals Summary

How do Aceragen's earnings and revenue compare to its market cap?
ACGN fundamental statistics
Market CapUS$39.85m
Earnings (TTM)-US$16.22m
Revenue (TTM)US$49.00k

813.3x

P/S Ratio

-2.5x

P/E Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report
ACGN income statement (TTM)
RevenueUS$49.00k
Cost of RevenueUS$9.25m
Gross Profit-US$9.20m
Other ExpensesUS$7.02m
Earnings-US$16.22m

Last Reported Earnings

Sep 30, 2022

Next Earnings Date

n/a

Earnings per share (EPS)-1.92
Gross Margin-18,771.43%
Net Profit Margin-33,095.92%
Debt/Equity Ratio0%

How did ACGN perform over the long term?

See historical performance and comparison